Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET (ReLUTH)
A Prospective Randomized Phase II Study Assess the Schema of Retreatment With Lutathera® ([177LU]LU-DOTA-TATE) in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Listed as NCT04954820, this PHASE2 trial focuses on Intestinal Well Differentiated Endocrine Tumor and Neuroendocrine Tumors and remains actively recruiting participants. Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle, it has been updated 12 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Oct 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jul 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Sep 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Institut du Cancer de Montpellier - Val d'Aurelle
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Bordeaux, France , Brest, France , Bron, France , Caen, France , Chambéry, France , Clermont-Ferrand, France , Clichy, France , Dijon, France , La Tronche, France and 15 more locations